Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 347 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetic Retinopathy Clear all
Completed No phase listed Observational

Resistance to Antibiotics in Patients Receiving Eye Injections

NCT02126423
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Conjunctival and nasopharyngeal swabs
Other
Lead sponsor
Prism Vision Group
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 9, 2026, 10:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

NCT07592273
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
36
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 10:41 PM EDT
Completed No phase listed Observational

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

NCT04477707
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Finerenone (BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

NCT03126786
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
IVT aflibercept, Sham SC, SC CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 1Phase 2 Interventional

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

NCT01724554
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 9, 2026, 10:41 PM EDT
Not listed No phase listed Observational

Retrospective Review of Proliferative Diabetic Retinopathy Patients

NCT03609996
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Panretinal Photocoagulation, Lucentis
Device · Drug
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Squalamine for the Treatment in Proliferative Diabetic Retinopathy

NCT01769183
View directory record Official record
Conditions
Retinal Neovascularization
Interventions
Squalamine Lactate ophthalmic solution 0.2%
Drug
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 9, 2026, 10:41 PM EDT
Completed No phase listed Observational

The Course of Response to Focal Photocoagulation for DME

NCT00442156
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Laser photocoagulation
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Palm Springs, California • Fort Lauderdale, Florida • Fort Myers, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of PER-001 in Participants With Diabetic Retinopathy

NCT06003751
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
Drug
Lead sponsor
Perfuse Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus to Treat Diabetic Macular Edema

NCT00711490
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 9, 2026, 10:41 PM EDT
Terminated No phase listed Observational

Tissue Studies of Human Eye Diseases

NCT00001310
View directory record Official record
Conditions
Retinal Disease, Corneal Disease, Diabetic Retinopathy, Uveitis, Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
3,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Not applicable Interventional Results available

OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits

NCT01875783
View directory record Official record
Conditions
Diabetes, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
OCT imaging
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Wellfleet, Massachusetts • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 9, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

NCT05463289
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes, Cystic Fibrosis-related Diabetes
Interventions
Point of Care Autonomous AI diabetic retinopathy exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 21 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

NCT01489189
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
Other · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
48
States / cities
Phoenix, Arizona • Loma Linda, California • Palm Springs, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 9, 2026, 10:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)

NCT01546766
View directory record Official record
Conditions
Diabetes, Retinal Disorders
Interventions
Pupillometry testing.
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

NCT00542178
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment, Standard BP control, Fenofibrate, Simvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
3,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 9, 2026, 10:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging

NCT00556114
View directory record Official record
Conditions
Glaucoma, Diabetic Retinopathy, Age-Related Macular Degeneration, Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
Optical Coherence Tomography
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 9, 2026, 10:41 PM EDT
Withdrawn Not applicable Interventional

Mobile Application to Enhance Diabetic Care

NCT01983917
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Diabetes Mobile Application
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 9, 2026, 10:41 PM EDT
Terminated No phase listed Observational

Effect of Panretinal Photocoagulation on Optic Nerve Head Topography

NCT00767884
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 9, 2026, 10:41 PM EDT
Terminated Phase 4 Interventional

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

NCT01591902
View directory record Official record
Conditions
Diabetic Retinopathy, HIV
Interventions
Tesamorelin, Placebo-Control
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy

NCT00917553
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
doxycycline monohydrate, Placebo
Drug
Lead sponsor
Thomas Gardner
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 9, 2026, 10:41 PM EDT
Terminated Phase 2 Interventional

Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema

NCT00701181
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Complications
Interventions
Laser Treatment, PF-04523655 high, PF-04523655 middle, PF-04523655 low
Procedure · Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Mesa, Arizona • Meza, Arizona • Peoria, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 9, 2026, 10:41 PM EDT
Completed No phase listed Observational

Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device

NCT04774822
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color Fundus Photography, Mydriatics Agent, Optical Coherence Tomography (OCT)
Procedure · Drug
Lead sponsor
RETINA-AI Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 9, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

NCT00295828
View directory record Official record
Conditions
Iris Neovascularization, Diabetic Retinopathy
Interventions
Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP)
Other · Procedure
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Oct 9, 2026, 10:41 PM EDT